chrisvoncsefalvay/vaers-outcomes huggingface dataset:
they themselves had a severe reaction after getting the Moderna vaccine; This spontaneous case was reported by an other health care professional and describes the occurrence of IMMUNISATION REACTION (they themselves had a severe reaction after getting the Moderna vaccine) in a  patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) (batch no. ASKU) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. On an unknown date, the patient experienced IMMUNISATION REACTION (they themselves had a severe reaction after getting the Moderna vaccine). At the time of the report, IMMUNISATION REACTION (they themselves had a severe reaction after getting the Moderna vaccine) outcome was unknown.        The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.   For mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. Treatment information was not provided.
Booster dose administered at 4 months instead of 5 months.  No treatment necessary.  No symptoms or adverse reactions noted.
Hospitalized for swelling to left upper and given IV antibiotics. Released from hospital 07/24/2000. Hospitalized X 2 days. Treated for cellulitis of injection site. D/C DGX is local reaction to tetanus toxoid w/ necrosis of fat.
Long term muscle fatigue/pain. Primarily noticed when doing chest exercises in the gym (I.e. barbell flat bench). Largely only a problem during flat bench, no issues with incline dumbbell press. Pain/soreness is isolated to the medial deltoid where the injection occurred, and only in the left arm where the injection occurred. Only began after dose 2. Noticed the week following the dose, pain persists. No treatment action taken.
Pt recvd 2 complete series of Engerix-B-DEC89, JAN90 & JUN90 & series 2 JAN90, FEB90, & JUL90 & had not response; 10MAR92 recvd a 7th dose of Engerix-B & 3 hrs later devel stomach pain, nausea, vomiting & diarrhea;
Higher than recommended dose of vaccine administered. Patient received up to 180mcg dose instead of 30mcg. Vial dilution not done.
Came into the ED on 11/12 with worsening R lower back pain and immobility.  was awaiting Rehab placement for PT/OT and was getting ativan and baclofen. Became more confused, lethargic. 11/17 baclofen and ativan stopped. Did not appear to be in alcohol withdrawal.  had a Grand Mal seizure on 11/19. Received ativan and seizure abated. only other new med was bactrim for UTI.  differential was alcohol withdrawal vs hospital acquired delirium vs due to medication vs Infection (UTI) (+ UA and UC but not UTI symptoms).   per neurology the single seizure like event likley due to GABAergic withdrawals (ETOH and lorazepam) no history of seizures. . EEG negative for seizures.
Pt. reports approx. 10 min after receiving MMR noted slight shortness of breath/throat tightness. Took 50mg Bendadryl with relief of symptoms within 20 minutes of medication.
Dose received: 3; light headiness; foggy; weak; within 6 hours of vax I contracted a UTI.; This is a spontaneous report from a contactable consumer(patient)  A 76-years-old non-pregnant female patient received booster dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot Number, Expiry date: not reported), via an unspecified route of administration, administered in left arm on 01Nov2021 (Age at vaccination: 76 years old) as dose 3 (booster), single for covid-19 immunization. Medical history included interstitial lung disease (ILD) from an unknown date and unknown if ongoing, and known allergies with penicillin, cipro, tramadol, codeine since an unknown date. Concomitant medications included magnesium, krill oil, colecalciferol (D3) tocopherol (VITAMIN E) all taken for an unspecified indication, start and stop date were not reported for all drugs. The patient previously took first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot Number: el92962, Expiry date: not reported), via an unspecified route of administration, administered in left arm on 27Jan2021 at 08:30 (Age at vaccination: 75 years old) as dose 1, single for covid-19 immunization and patient previously took second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot Number: en6200, Expiry date: not reported), via an unspecified route of administration, administered in left arm on 17Feb2021 at 08:15 (Age at vaccination: 75 years old) as dose 2, single for covid-19 immunization. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine, patient was not diagnosed with COVID-19 prior to vaccination, patient has not been tested for COVID-19 since the vaccination. On 01Nov2021 patient received 3rd dose (booster dose) of covid-19 vaccine and patient experienced light headiness, foggy, weak and within 6 hours of vax patient contracted a urinary tract infection (UTI). Patient did not receive any treatment for the events. Outcome for events light headiness, foggy, weak and within 6 hours of vax patient contracted a urinary tract infection was recovered on an unspecified date in 2021.  Follow-up attempts are completed. No further information is expected.
pt recv vax & fell to the floor, eyes rolled back, back arched;circumoral cyanosis;02 applied;heart regular-no resp distress;color returned w/02;sent to ER for eval & parent comfort;ER report sycopal episode;
Vaccine injection went fine it did not hurt at all, but I sat down for observation and within 2 minutes I felt mildly dizzy and then brief chest pressure and a wave of nausea.  The chest pressure went away quickly but I was more flush then usual, about 15 min in my eyes felt watery and itchy. Went to ER to be observed, EKG came out fine. 118/72 HR 68 . Everything was fine. No meds prescribed, just observation, stayed about 90 min in observation by the time I eft I was just mildly nauseated. By the time I arrived home, 2 hours later all symptoms were resolved.
The vial was not diluted properly, it was only diluted with 0.8mls; The vial was not diluted properly, it was only diluted with 0.8mls; This is a spontaneous report from a non-contactable pharmacist. A 17-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an intramuscular route of administration in the left arm on 09Apr2021 (at the age of 17-year-old) as a 0.3 ml single dose for COVID-19 immunisation. The patient did not have any medical history and no known allergies to medications, food or other products. It was unknown if the patient received any medication within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 09Apr2021, the patient was given a dose of 0.3 ml but the vial was not diluted properly, it was only diluted with 0.8mls.  No follow-up attempts are possible. No further information is expected.
No other adverse events reported; Caller reports that a husband and wife was administered expired doses of MMR II.; This spontaneous report was received from a registered nurse concerning a male patient.  The patient's medical history, concurrent conditions, and concomitant therapies were not reported.  On 12-MAY-2022, the patient was vaccinated with an expired dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) subcutaneous injection, (lot #T016197, has been verified to be valid, expiration date: 11-MAY-2022), administered for prophylaxis (strength, and route of administration were not provided). No further information was provided, and no other adverse events were reported.   This is one of two reports received from the same source.; Sender's Comments:  US-009507513-2205USA003756:
dizziness, felt faint, nausea approx 10 mins p/vax; hives devel 45 mins later; pt taken to ER;
The vaccinator used a 5/8" needle to vaccinate the patient in their left anterolateral thigh.
This spontaneous report as received from a pharmacist refers to a newborn male patient of unknown age. On 07-OCT-2012 19:07, the patient was vaccinated with RECOMBIVAX HB that had been exposed to temperatures below 32F for 6 hours. During that 6 hour time period, the vaccine was exposed to 28.8F for 1.5 hours. Administration route was not reported. Two lot# were involved and the lot# were reported as: 0294AE, expiry date on 06-SEP-2014; and 0385AE, expiry date on 08-NOV-2014. It was unspecified which lot# the patient was administered. The outcome of event was unknown. It was unspecified if the patient sought medical attention. This is one of several reports received from the same source. Additional information has been requested.
MODERNA COVID VACCINE #3 GIVEN 11/30/21, LOT #027H21B; pt had a positive COVID test in the nursing home; DNR; pt not in respiratory distress during course of illness; appetite decreased over time; taking only sips of liquid, and unable to swallow medication the day he passed in the nursing home
COAGULOPATHY, UNSPECIFIED TYPE 7/7/2021 HYPOXIA  CHRONIC RESPIRATORY FAILURE 11/29/2022 HYPOXIA  HYPOXIA 5/13/2021 HYPOXIA  COAGULOPATHY, UNSPECIFIED TYPE 7/7/2021 ATRIAL FIBRILLATION, PAROXYSMAL  CHRONIC RESPIRATORY FAILURE 11/29/2022 ATRIAL FIBRILLATION, PAROXYSMAL  HYPOXIA 5/13/2021 ATRIAL FIBRILLATION, PAROXYSMAL  COAGULOPATHY, UNSPECIFIED TYPE 7/7/2021 ATHEROSCLEROSIS OF AORTA  CHRONIC RESPIRATORY FAILURE 11/29/2022 ATHEROSCLEROSIS OF AORTA  HYPOXIA 5/13/2021 ATHEROSCLEROSIS OF AORTA  COAGULOPATHY, UNSPECIFIED TYPE 7/7/2021 ATHEROSCLEROSIS OF AORTA  CHRONIC RESPIRATORY FAILURE 11/29/2022 ATHEROSCLEROSIS OF AORTA  HYPOXIA 5/13/2021 ATHEROSCLEROSIS OF AORTA
Fatigue; Heart Palpitation; Severe headache; 2nd Vaccine arm developed hard ball size of a basball, tender to the touch and felt hot; 2nd Vaccine arm developed hard ball size of a basball, tender to the touch; 2nd Vaccine arm developed hard ball size of a basball, tender to the touch and felt hot; This spontaneous case was reported by a consumer and describes the occurrence of PALPITATIONS (Heart Palpitation), VACCINATION SITE WARMTH (2nd Vaccine arm developed hard ball size of a basball, tender to the touch and felt hot), FATIGUE (Fatigue), HEADACHE (Severe headache) and VACCINATION SITE MASS (2nd Vaccine arm developed hard ball size of a basball, tender to the touch and felt hot) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Blood pressure high.   On 03-Jan-2022, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Jan-2022, the patient experienced HEADACHE (Severe headache). On an unknown date, the patient experienced PALPITATIONS (Heart Palpitation), VACCINATION SITE WARMTH (2nd Vaccine arm developed hard ball size of a basball, tender to the touch and felt hot), FATIGUE (Fatigue), VACCINATION SITE MASS (2nd Vaccine arm developed hard ball size of a basball, tender to the touch and felt hot) and VACCINATION SITE PAIN (2nd Vaccine arm developed hard ball size of a basball, tender to the touch). At the time of the report, PALPITATIONS (Heart Palpitation), FATIGUE (Fatigue) and HEADACHE (Severe headache) had not resolved and VACCINATION SITE WARMTH (2nd Vaccine arm developed hard ball size of a basball, tender to the touch and felt hot), VACCINATION SITE MASS (2nd Vaccine arm developed hard ball size of a basball, tender to the touch and felt hot) and VACCINATION SITE PAIN (2nd Vaccine arm developed hard ball size of a basball, tender to the touch) had resolved.            Concomitant medications included unspecified high blood pressure medications.  It was reported that vaccine made the patient so severely sick and did not feel the same. Patient did not receive any treatments.   This case was linked to MOD-2022-477408 (Patient Link).
positive COVID-19 test with symptoms; positive COVID-19 test with symptoms; This is a spontaneous report from a contactable consumer (patient).  A 60-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL3302), via an unspecified route of administration at arm right on 20Jan2021 at 10:00 at single dose for COVID-19 immunization. The patient medical history included diabetes from an unknown date and ongoing. The patient's concomitant medication included metformin.  The patient experienced COVID-19 on 27Jan2021 (she got all the symptoms: sinus, headache, body aches, pain, chills, joint pain, fever). The patient was admitted to emergency room due to the event. The patient underwent lab test and procedure which included blood test and chest X-ray both on an unspecified date and both resulted that "everything was good" values not provided, in Jan2021 body weight: between 114-115 lbs, but probably 110 (lost a lot of weight in the past two weeks because of the virus) and SARS-CoV-2 test (nasal swab): positive on 27Jan2021. Therapeutic measures were taken as result of COVID-19 and included treatment with benzonatate (lot: 7893614, dose: 100 mg; one pill a day), ivermectin (dose: 3 mg, 4 pills a day for 2 days, exp: 28Apr2021), prednisone (dose: 20 mg,  3 tablets once daily lot: 7893618 ), azithromycin (dose: 500 mg, for five days, lot: 7893308). Medications she was prescribed in the emergency room were helping a little bit. The patient outcome of the events was unknown.
Swelling in upper left arm and red spots like bumps below vaccination site, extreme itching and almost looked like welps..showed pharmacy staff..went to my local dr and she diagnosed it as adverse reaction to the vaccine,  received steroid shot us antibiotics and triamcinolone medications
Rush of flow in stomach and arm. Nausea, Chest tightness, Hard time breathing, Throat tightness, Heavy sweating, Dizziness, Tingling feeling in whole body.
Immediately after influenza vaccination, the patient developed R shoulder pain near the injection site that has continued until today (23 Jan 2017). On exam, she suffers from decreased range of motion so there seems to be some inflammation/involvement of the shoulder joint where she received the vaccine.
Information has been received on 11-SEP-2018 regarding a case in litigation from a lawyer and a male consumer of unknown age. The patient's concurrent conditions, medical history and concomitant medications are unknown. On or about 29-DEC-2012, the patient was inoculated with ZOSTAVAX (lot number and expiration unknown) unknown route at a pharmacy as recommended for routine adult health maintenance for the long-term prevention of shingles. The vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster or shingles. In 2016, the patient was treated by a physician at a medical facility for a persistent vesicular outbreak accompanied by weakened immune symptoms, which was diagnosed as herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX and/or despite receiving the ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses and pain and suffering and other damages. Additional information has been requested.
Pt reported pain, redness, & swelling @ inject site p/receiving Td following unspecified laceration injury;
Patient complained of episodes of numbness on left side of face along with difficulty speaking lasting up to 5 minutes. She has had 4 episodes since vaccination, last one was 1 week ago
Case number PHEH2012US018681 is an initial spontaneous report received from a health care professional on 05 Sep 2012 with the follow-up received on 16 Oct 2012: This report refers to an 11-year-old female child. She was vaccinated with MENVEO (batch number: M11082 and expiry date: 31 May 2014) intramuscularly in the left arm on 31 Aug 2012 at 13:41 pm. She was also vaccinated with FLUMIST (other manufacture) on 31 Aug 2012. These vaccine had reached up to 11 degree Celsius for 30 to 60 minutes. No adverse event was reported following this administration error. Follow-up received on 16 Oct 2012: Updated patient height and weight, vaccine route of vaccination, site of vaccination, time of vaccination and concomitant vaccine.
Admission Date: 3/20/2023 Discharge Date: Mar 23, 2023  PRESENTING PROBLEM: Hypoxia  COPD exacerbation  Acute respiratory failure with hypoxia  COVID-19    HOSPITAL COURSE: Patient is a 73 y.o. female with past medical history significant for chronic obstructive pulmonary disease, sustained SVT, and tobacco use disorder who presented with shortness of breath and is found to have COVID-19 infection as well as evidence of acute bronchitis on CTA thorax.  No evidence of pulmonary embolism.  She was significantly wheezy and felt to be in exacerbation of chronic obstructive pulmonary disease.  She was given IV steroids and scheduled nebulizers with significant improvement.  She was additionally started on remdesivir and received 4 days of this.  She initially required 2 L nasal cannula and was intermittently able to wean down to 1 L. additionally on presentation she had nonsustained SVT.  Initial EKGs concerning for possible Wolff-Parkinson-White, electrophysiology team was consulted felt this was less likely.  She was started on diltiazem with significant improvement.  On day of discharge patient is feeling subjectively improved although still does require 1 L nasal cannula to maintain saturations greater than 92%.  Patient is subjectively dyspneic under 92%.  Patient does have oxygen at home as she has been using this nightly since her prior hospitalization.  She will continue to wean oxygen as able at home.  She will follow with our transition to home program.  Her daughter is very informed and was updated on plan day of discharge.
4/18 developed rash behind ears, back of neck and on face then went to arms, torso and legs. Had running nose : raspy breathing. Saw on 4/23.
This spontaneous report was received from a medical assistant and refers to an unspecified number of patients of unknown age and gender. The patients' concurrent conditions and medical history were not reported. On an unknown date, the patient was vaccinated with improperly stored doses of VAQTA which had a lot# of L023232, and an expiration date of 25-FEB-2017 (concentration, dose, route and anatomical place of vaccination were not provided). Which were exposed to a temperature of 32.7 F for 31 hours. There were no previous excursion and a data logger was involved. Information regarding concomitant therapies was not reported. No product quality complaint was involved. This is one of several reports from the same reporter. Additional information has been requested.
I had a PNEUMOVAX 23 injection and the pain in my arm kept me awake that night. The next day was just as bad and the pain moved to the underside of my arm. I am very fatigued.
No adverse effects; accidental administration of PROQUAD in place of MMR II concomitantly with VARIVAX in patient; accidental administration of PROQUAD in place of MMR II concomitantly with VARIVAX in patient resulting in an extra dose ofVARIVAX; This spontaneous report was received from a physician referring to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, concomitant therapies and drug reactions/allergies were not provided.  On 27-AUG-2019, the patient was accidental vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) lot # S003176, expiration date: 30-JUL-2020 (dose, unit, and route of administration were not reported) in place of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (Wrong product administered) concomitantly with varicella virus vaccine live (oka/merck) (VARIVAX) (dose, unit, lot#, expiration date and route of administration were not reported) for prophylaxis. This resulting in an extra dose of varicella virus vaccine live (oka/merck) (VARIVAX) (Extra dose administered). No adverse effects were reported.
Extreme lupus flare. I was in complete remission for last 10 years - worked very hard to get rid off lupus medication so I can become pregnant. Just after 1 week of pfizer, I got severe lupus flare - I couldn't move my hand or feet for a month. My bloodwork shows extreme lupus flare - to get better I had to start taking high risk high doses of different immune suppressants. I can't become pregnant again due to those medication. Thank you pfizer and cdc for ruining my life.
Information has been received from a physician concerning a "74 year old" female who in April 2007, was vaccinated with a single dose of ZOSTAVAX (Merck) (dose, route and lot number unspecified). There was no concomitant therapy. A "couple of weeks ago" (approximately 10-APR-2009), the patient came down with shingles. The patient sought unspecified medical attention. The outcome of the patient was unknown. Additional information has been requested.
He also stated that he had sore arm after each dose; This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (He also stated that he had sore arm after each dose) in a 70-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 030M20A, 032M20A and 056M21A) for COVID-19 vaccination.     Patient had no allergies. patient never had COVID + test or diagnosis.    On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 09-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In February 2021, the patient experienced PAIN IN EXTREMITY (He also stated that he had sore arm after each dose). At the time of the report, PAIN IN EXTREMITY (He also stated that he had sore arm after each dose) had not resolved.            No concomitant medications was reported. Patient had no acute or chronic illnesses at the time of vaccination.  Other vaccines given within 1 month prior to Moderna COVID-19 vaccine (type, brand, lot, route, dose #) was flu vaccine wihtin the last couple of months.  The event onset date for Sore arm for dose 2 was Mar-2021 and for dose 3 was dec-2021.  Adverse event cause patient to seek medical care (office visit, Urgent care, ER, hospitalized) reported as no. The patient did not experienced a similar event in the past.  No treatment drug details was reported.   This case was linked to MOD-2022-675716 (Patient Link).
Fever; Headache; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the parent.  A female patient received bnt162b2 (BNT162B2), administration date 25Jun2021 (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (1ST DOSE), for COVID-19 Immunization. The following information was reported: PYREXIA (non-serious) with onset Jun2021, outcome "unknown", described as "Fever"; HEADACHE (non-serious) with onset Jun2021, outcome "unknown", described as "Headache". No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient was pale and diaphoretic after receiving the vaccine. In the past, passed out when giving blood. Did not eat or drink before getting the vaccine. Given juice and water.